Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

 Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

Shots:

  • Obsidian to receive $75M in equity, up front, research milestones and is eligible to receive ~$1.3B as research, development, regulatory, and commercial milestones across up to five potential programs. Additionally, Obsidian will receive royalties on sales of products that emerge from the collaboration
  • Obsidian will deploy its cytoDRiVE platform to discover controllable genetic therapies to treat serious diseases. Vertex to get an exclusive option to license WW rights to candidates discovered and developed under the collaboration
  • Upon option exercise, Vertex will be responsible for further pre/clinical development and commercialization of the therapies

Click here to­ read full press release/ article | Ref: Business Wire | Image: Crunshbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post